---
title: "DexCom, Inc. (DXCM.US) — 公司概況"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/DXCM.US/overview.md"
symbol: "DXCM.US"
name: "DexCom, Inc."
parent: "https://longbridge.com/zh-HK/quote/DXCM.US.md"
datetime: "2026-04-05T03:02:46.035Z"
locales:
  - [en](https://longbridge.com/en/quote/DXCM.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DXCM.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DXCM.US/overview.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/DXCM.US/overview.md) | [简体中文](https://longbridge.com/zh-CN/quote/DXCM.US/overview.md)


# DexCom, Inc. (DXCM.US) — 公司概況

## 基本資訊

| 項目 | 詳情 |
|------|--------|
| 行業 | Health Care Equipment |
| 交易所 | US Market |
| 地址 | 6340 Sequence Drive, San Diego, California, United States |
| 官網 | [www.dexcom.com](https://www.dexcom.com) |

## 公司簡介

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

## 核心管理層

| 名稱 | 職位 |
|------|-------|
| Kevin Ronald Sayer | Executive Chairman of the Board |
| Jacob Steven Leach | President, CEO & Director |
| Jereme M. Sylvain | Executive VP, CFO & Chief Accounting Officer |
| Michael Jon Brown | Executive VP & Chief Legal Officer |
| Sadie M. Stern | Executive VP & Chief Human Resources Officer |
| Nicholas Augustinos | Independent Director |
| Mark G. Foletta | Lead Independent Director |
| Bridgette P. Heller | Independent Director |

## 主要股東

| 名稱 | 佔比 | 報告日期 |
|------|-------|-------------|
| The Vanguard Group, Inc. | 12.75% | 2025-12-31 |
| BlackRock, Inc. | 10.35% | 2025-12-31 |
| State Street Global Advisors, Inc. | 4.70% | 2025-12-31 |
| Baillie Gifford & Co. | 4.04% | 2025-12-31 |
| Geode Capital Management, LLC | 2.86% | 2025-12-31 |
| UBS Asset Management AG | 2.58% | 2025-12-31 |
| AllianceBernstein L.P. | 2.24% | 2025-12-31 |
| Norges Bank Investment Management | 1.89% | 2025-12-31 |
| Jennison Associates LLC | 1.50% | 2025-12-31 |
| JP Morgan Asset Management | 1.31% | 2025-12-31 |

## 業務構成

| 業務線 | 營收 | 佔比 |
|---------|---------|-------|
| Patient Monitoring Equipment | 4662000000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "DexCom, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Patient Monitoring Equipment",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地區分佈

| 地區 | 營收 | 佔比 |
|--------|---------|-------|
| United States (U.S.) | 3334900000 | 71.53% |
| International | 1327100000 | 28.47% |


---

> **免責聲明: 本文僅供參考，不構成任何投資建議。**